About
29.96USD-0.92 -2.98%
Closed • Updated at 00:25 GMT+00:00Market Cap$21.55B
Volume5.87M
Beta0.61
RSI54.60
Gross Margin43.91%
Roivant Sciences Ltd. — investor relations, events, news, and company updates on 6ix.
Latest News
May 20 2026
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
May 20 2026
Roivant Sciences : Annual Report for Fiscal Year Ending March 31, 2025 (Form 10-K)
May 11 2026
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
Apr 2 2026
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Apr 2 2026
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
Community Chat
Ask AI
Try asking
Google Übersetzer